Also favorable are a slow tumor growth and tumor size <5 cm, female gender, absence of extrathyroidal invasion and nodal involvement, encapsulated tumor with no or minimal capsular invasion and the presence of areas of differentiated carcinomas without BRAF or RAS or TP53 mutations. This evidence concerns the gene BRAF and neoplasm.